Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy

Polymorphisms of genes encoding cytokines predict the risk of high-grade bladder cancer and outcomes of BCG immunotherapy

Bibliographic Details
Main Authors:	Wojciech Krajewski, Lidia Karabon, Anna Partyka, Anna Tomkiewicz, Sławomir Poletajew, Andrzej Tukiendorf, Anna Kołodziej, Romuald Zdrojowy
Format:	Article
Language:	English
Published:	Termedia Publishing House 2020-04-01
Series:	Central European Journal of Immunology
Subjects:	gene polymorphisms non-muscle-invasive bladder cancer bacillus calmette-guerin recurrence progression
Online Access:	https://www.termedia.pl/Polymorphisms-of-genes-encoding-cytokines-predict-the-risk-of-high-grade-bladder-cancer-and-outcomes-of-BCG-immunotherapy,10,40452,1,1.html

Similar Items

Intravesical immunotherapy in nonmuscle invasive bladder cancer
by: Jan-Friedrich Jokisch, et al.
Published: (2015-01-01)

Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature
by: Oreoluwa Oladiran, et al.
Published: (2020-03-01)

Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer
by: Chun Jye Lim, et al.
Published: (2021-01-01)

Reiter’s syndrome occurred following intravesical BCG immunotherapy: Case presentation
by: Fatih Elbir, et al.
Published: (2015-06-01)

Single course of intravesical Bacillus Calmette–Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: A prospective randomized study
by: Mohamed Bakr Mohamed, et al.
Published: (2020-01-01)

Asymptomatic renal BCG granulomatosis: An unusual complication of intravesical BCG therapy for carcinoma urinary bladder
by: Suresh Bhat, et al.
Published: (2015-01-01)

A review on the evolution of immunotherapy in bladder carcinoma
by: Milena Gulinac, et al.
Published: (2020-10-01)

Intravesical Bacillus Calmette-Guérin (BCG) treatment's severe complications: A single institution review of incidence, presentation and treatment outcome
by: R. Waked, et al.
Published: (2020-05-01)

Bladder Cancer Immunotherapy by BCG Is Associated with a Significantly Reduced Risk of Alzheimer’s Disease and Parkinson’s Disease
by: Danielle Klinger, et al.
Published: (2021-05-01)

Weekly intravesical bacillus Calmette-Guerin (BCG) alternating with epirubicin in Ta and T1 urothelial bladder cancer: An approach to decrease BCG toxicity
by: Bedeir Ali-El-Dein, et al.
Published: (2013-01-01)

Granulomatous Hepatitis Following Intra-Vesical Instillation of Bacillus Calmette–Guérin for Treatment of Bladder Cancer
by: Elsa Alves Branco, et al.
Published: (2021-07-01)

Intravesical BCG immunotherapy: Sepsis and multiorgan failure developed after traumatic catheterization
by: Tufan Cicek, et al.
Published: (2014-02-01)

Reactive Arthritis – A Rare Complication of Intravesical BCG Instillation
by: Marta Freixa, et al.
Published: (2020-02-01)

Tuberculous epididymo-orchitis secondary to Bacillus Calmette-Guérin (BCG) in non-muscular invasive bladder cancer
by: Luis Felipe Lara Moscoloni, et al.
Published: (2021-07-01)

New-onset guttate psoriasis following intravesical immunotherapy of Bacillus Calmette–Guerin
by: Chih-Tsung Hung, et al.
Published: (2012-09-01)

Efficacy of bladder instillations with mitomycin or bacillus Calmette–Guérin in patients with T1 high-grade bladder cancer: Experience from a single center
by: Li-Wen Chang, et al.
Published: (2019-01-01)

Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
by: Jeffrey Huang, et al.
Published: (2017-09-01)

Bacillus Calmette-Guerin Increases Base Excision Repair in Bladder Cancer Cells
by: Selçuk Keskin, et al.
Published: (2021-03-01)

Regression of the Sweet's syndrome after Bacillus Calmette-Guérin therapy: A bladder cancer case report
by: İbrahim Halil Baloglu, et al.
Published: (2020-07-01)

Mycobacterium bovis infection of a femorofemoral bypass graft following intravesical Bacillus Calmette–Guérin (BCG) immunotherapy
by: Ryan K. Meyer, M.D., et al.
Published: (2020-05-01)

Bacillus Calmette–Guérin and Bladder Cancer
by: Azad H.A. Razack
Published: (2007-10-01)

A randomized trial comparing low dose (40 or 80 mg) with standard dose (120 mg) of bacillus Calmette-Guerin for superficial bladder cancer
by: Vivek Vijjan, et al.
Published: (2006-01-01)

Bacillary Prostatitis after Intravesical Immunotherapy:A Rare Adverse Effect
by: Ana Joaquim, et al.
Published: (2012-02-01)

Economic impacts of the Bacillus Calmette-Guérin (BCG) therapy shortage and the proposed solutions for patients with non-muscle invasive bladder Cancer in Aseer Province, Saudi Arabia
by: Mishari H M Alshyarba, et al.
Published: (2020-01-01)

Optimization of BCG Therapy Targeting Neutrophil Extracellular Traps, Autophagy, and miRNAs in Bladder Cancer: Implications for Personalized Medicine
by: Chenyu Mao, et al.
Published: (2021-09-01)

Partial Versus Complete Bacillus Calmette-Guérin Intravesical Therapy and Bladder Cancer Outcomes in High-risk Non–muscle-invasive Bladder Cancer: Is NIMBUS the Full Story?
by: Michael E. Rezaee, et al.
Published: (2021-04-01)

Maintenance bacillus Calmette–Guérin therapy prolongs recurrence-free survival in non-muscle-invasive bladder cancer: A real-world experience
by: Chung-Yi Liu, et al.
Published: (2015-06-01)

Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-01-01)

Systemic granulomatous reaction secondary to treatment of bladder cancer with Bacillus Calmette-Guerin
by: Caterina Giovanna Valentini, et al.
Published: (2012-06-01)

A case of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) strain meningitis and ventriculitis following BCG vaccination
by: Mihoko Furuichi, et al.
Published: (2020-11-01)

New Roadmaps for Non-muscle-invasive Bladder Cancer With Unfavorable Prognosis
by: Katia Pane, et al.
Published: (2020-07-01)

Post-Bacille Calmette–Guerin surveillance for non-muscle invasive bladder cancer: do random biopsies offer an advantage?
by: Nassib Abou Heidar, et al.
Published: (2021-03-01)

NFκB-Activated COX2/PGE<sub>2</sub>/EP4 Axis Controls the Magnitude and Selectivity of BCG-Induced Inflammation in Human Bladder Cancer Tissues
by: Omar M. Ibrahim, et al.
Published: (2021-03-01)

Transdifferentiation of Small Cell Carcinoma of the Urinary Bladder from Urothelial Carcinoma after Transurethral Resection of a Bladder Tumor, Intravesical Bacillus Calmette-Guerin Instillation, and Chemotherapy: A Case Report
by: Kento Morozumi, et al.
Published: (2016-11-01)

Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications
by: Magdalene Joseph, et al.
Published: (2019-11-01)

Evaluation of Children with Complication of BCG Vaccination in North of Iran
by: Mohammad Sadegh Rezai, et al.
Published: (2017-03-01)

Mesane içi BCG immünoterapisi: Travmatik kateterizasyon sonrası gelişen sepsis ve çoklu organ yetmezliği
by: Tufan ÇİÇEK, et al.
Published: (2014-07-01)

Severe pneumonia after intravesical BCG instillation in a patient with invasive bladder cancer: case report and literature review
by: G. Caramori, et al.
Published: (2015-11-01)

The comparison of efficacy between the connaught and tice strains of bacillus calmette-guérin in patients with non-muscle-invasive bladder cancer in Taiwan
by: Chen, C.-H, et al.
Published: (2022)

Recurrence and progression in nonmuscle invasive transitional cell carcinoma of urinary bladder treated with intravesical Bacillus Calmette–Guerin: A single center experience and analysis of prognostic factors
by: Shouki N Bazarbashi, et al.
Published: (2016-01-01)

Cannot write session to /tmp/vufind_sessions/sess_7gbpcel45el9ucpvcn93rgrsqs